# OnCo record pik3ca-hotspot-mutation (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/pik3ca-hotspot-mutation/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "pik3ca-hotspot-mutation" ;
  schema:name "PIK3CA mutation"@en ;
  schema:alternateName "PIK3CA mutation"@en, "PIK3CA-mutated"@en, "PIK3CA H1047R"@en, "PIK3CA E545K"@en, "PIK3CA E542K"@en, "PIK3CA hotspot"@en, "PI3K mutation breast cancer"@en ;
  schema:description "PIK3CA mutations in the helical and kinase domains are found in about 40 percent of hormone-receptor-positive breast cancers. Alpelisib, inavolisib and capivasertib are approved for tumours that carry them."@en ;
  schema:url <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20b4e18-7a4b-4500-a08f-06c6dab0ee5b>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5de59f5b-e5db-410f-b692-658686ef4107>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d698c106-2322-401e-b738-cbd83c843ecf> ;
  onco:tag "biomarker", "pi3k" ;
  onco:related <https://onco.cc/biomarkers/akt1-e17k/>, <https://onco.cc/biomarkers/pten-alteration/>, <https://onco.cc/biomarkers/esr1-mutation-ctdna/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/>, <https://onco.cc/cancers/endometrial/> ;
  onco:drugs <https://onco.cc/drugs/alpelisib/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/hyperglycaemia/>, <https://onco.cc/terms/ngs/> .